For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of this treatment and the formulated version represents a true change. These groundbreaking therapies protect the transthyretin protein, halting its destructive build-up and lessening the burden of the condition . People are now seein